Last Updated on Jun 15, 2021 by Manonmayi

After Shyam Metalics IPO opened on Mon this week, joining the ranks of Fortis and Apollo Hospitals is Hyderabad-based Krishna Institute of Medical Sciences (KIMS). The company is set to make a debut in the market with its initial public offering (IPO) on 16th Jun 2021 along with Dodla Dairy.

Private hospitals have been at the war-front in the battle against the coronavirus and they continue to play a vital role in the immunisation drive in the country. KIMS is hoping this newly-gained special importance will attract investors to its shores while also banking on the bull run the stock market is witnessing to fan their growth. Here’s all there is to know about the KIMS Hospitals upcoming IPO!

This article covers:

About Krishna Institute of Medical Sciences Ltd

Incorporated in the year 1973, KIMS is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The Hyderabad-based hospital chain offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities, and an additional quaternary healthcare facility in tier-1 cities. The company currently operates 9 hospitals across Andhra Pradesh and Telangana with an aggregative bed capacity of 3,000+ as of 31st Mar 2021.

Highlights of KIMS Hospitals

KIMS has grown from a single hospital to a chain of 9 multi-speciality hospitals within 2 decades through organic growth and strategic acquisitions. Here are some highlights of the hospital.

  • Their aggressive network expansion is relatively new. KIMS acquired hospitals in Ongole in FY 2017-2018, Vizag and Anantapur in FY 2018-2019 and Kurnool in FY 2019-2020
  • According to a CRISIL report, KIMS operates one of the largest private sector hospitals in one location in India – at Secunderabad – with a capacity of 1,000 operational beds
  • KIMS achieved a pre-COVID bed occupancy rate of 80.43% as of 2020
  • They have a strong strategic hold in the healthcare segment in South India wherein they understand the regional customer, the culture, mindset, and nuances
  • KIMS is one of the premier hospitals for the organ transplant in South India and is also one of the first in the country to invest in Robotic Sciences
  • They have been one of the front-runners for COVID treatment in Andhra Pradesh and Telangana

Services provided by KIMS

KIMS provides a comprehensive range of healthcare services across 25+ specialties and super specialties, including:

  • Cardiac sciences
  • Neurosciences
  • Gastric sciences
  • Oncology
  • Orthopaedics
  • Organ transplant
  • Renal sciences
  • Mother and child care

Subsidiaries of KIMS Hospitals

  • Arunodaya Hospitals Private Limited (“AHPL”)
  • KIMS Hospital Enterprises Private Limited (“KHEPL”)
  • Iconkrishi Institute of Medical Sciences Private Limited (“ICIMSPL”)
  • Saveera Institute of Medical Science Private Limited (“SIMSPL”)
  • KIMS Hospital Kurnool Private Limited (“KHKPL”)
  • KIMS Hospitals Private Limited (“KHPL”)
  • KIMS Swastha Private Limited (“KSPL”)
  • KIMS Cuddles Private Limited (“KCPL”)
  • KIMS Hospital (Bhubaneswar) Private Limited (“KHBPL”)

Notable investors of the company

  • General Atlantic Singapore KH Pte Ltd.
  • Dr. Bhaskara Rao Bollineni
  • Rajyasri Bollineni
  • Bollineni Ramanaiah Memorial Hospitals Private Ltd.

About KIMS Hospitals IPO

KIMS is issuing an initial public offering (IPO) to raise Rs 2,144 cr. Here are the details of the IPO:

  • The IPO opens for subscription on 16th Jun 2021 and closes on 18th Jun 2021
  • The price band of the issue is Rs 815-825 per share
  • The minimum lot comprises 18 shares. Retail investors can bid for either one lot or its multiples thereafter. The maximum number of lots you can apply for is 13
  • The IPO includes a fresh issue of Rs 200 cr and an Offer For Sale (OFS) of up to 2.35 cr equity shares by the promoters and existing shareholders. This includes roughly 1.6 cr shares by the biggest investor in the company – General Atlantic Singapore KH Pte.
  • The issue may be listed on BSE and NSE on 28th Jun 2021

Promoters and investors exiting their share

The promoters of the company are:

  1. Dr. Bhaskara Rao Bollineni
  2. Dr. Abhinay Bollineni
  3. Rajyashri Bollineni
  4. Bollineini Ramanaiah Memorial Hospitals Private Limited
  5. Adwik Bollineni

Through the OFS, Dr Bhaskara Rao Bollineni, Rajyasri Bollineni, Bollineni Ramanaiah Memorial Hospital Private Limited and other existing shareholders will be exiting a part of their position in the company.

Reservation of the IPO for various investor categories

75% of the offer is reserved for Qualified Institutional Buyers (QIBs), 15% is reserved for Non-Institutional Buyers (NIBs) and 10% is reserved for retail investors.

The offer also includes a reservation of up to Rs 20 cr worth of equity shares for the employees. An additional discount of Rs 40 will be provided to employees who bid in the reserved portion.

Utilisation of the IPO proceeds

The company plans on using the proceeds from the Rs 200 cr fresh issue as follows:

  • To repay its existing borrowings, which amounts to roughly Rs 150 cr
  • Use the remaining Rs 50 cr towards general corporate purposes including capital expenditure and partnerships, among other expenses

Book running lead managers and registrar of the IPO

Kotak Mahindra Capital Company, Credit Suisse, IIFL Securities, and Axis Capital have been appointed as book runners to manage the public issue. Link Intime India Private Ltd. has been appointed as the registrar to the KIMS’ IPO issue.

Financials of the company

KIMS has recorded steady growth in revenues as well as profitability in the past few years. Here are some details:

  • The company observed an increase in the profits from Rs 115 cr in FY 2019-2020 to Rs 205 cr in FY 2020-2021
  • Revenue jumped from Rs 1,129 cr in FY 2019-2020 to Rs 1,340 cr in FY 2000-2021, roughly a 19% y-o-y increase

In FY 2020-2021, 18% of KIM’s revenue came from cardiac sciences, 13% from neurosciences, 9% from renal sciences, and 5% from orthopaedics.

Here’s a quick summary of the company financials:

Peer comparison

KIMS competes with the likes of Narayana Hrudayalaya, Apollo Hospitals, Manipal Hospitals, and Healthcare Global. According to an Axis Capital report, the 3-yr compounded annual growth rate (CAGR) of KIMS is the best amongst major hospital players. Here’s a chart depicting the same.

Competitive peers

Strengths of the company

  • KIMS is one of the largest private sector healthcare groups in southern India with 3,064 beds, which is almost twice as many beds when compared to the 2nd largest healthcare provider in the same region
  • The company has shown exemplary growth from a single 200-bed hospital to a multidisciplinary super-speciality hospital chain with over 3,000 beds spread across 9 network hospitals
  • KIMS has expanded its business by successfully completing 4 significant acquisitions from FY 2017-2018 to FY 2019-2020 including KIMS Ongole, KIMS Anantapur, KIMS Kurnool, and KIMS Vizag, which further strengthens its hold on the healthcare sector in South India
  • They are the market leader in Andhra Pradesh and Telangana for providing affordable and quality healthcare services

Risks of the company

  • There is an extremely high level of dependency on healthcare professionals with the top 10 doctors contributing roughly 22% of the total receipts for the hospital chain
  • A major chunk of revenue comes from the company’s operations in Hyderabad
  • According to the company, despite revenue and profit increase, the hospital experienced a degrowth of 3.96% in their outpatient volume due to COVID-related lockdowns, travel restrictions, and quarantine procedures

As always, we advise you to do your own research before applying for this IPO. Read up about the company and its operations extensively before applying!

Inline Feedbacks
View all comments
55,00,000+ users trust Tickertape for Investment Analysis!
55,00,000+ users trust Tickertape for Investment Analysis!

The blog posts/articles on our platform are purely the author’s personal opinion and do not necessarily represent the views of Anchorage Technologies Private Limited (ATPL) or any of its associates. The content in these posts/articles is for informational and educational purposes only and should not be construed as professional financial advice. Should you need such advice, please consult a professional financial or tax advisor. The content on our platform may include opinions, analysis, or commentary, which are subject to change, without notice, based on market conditions or other factors. Further, the use of any third-party websites or services linked on the website is at the user's discretion and risk. ATPL is not responsible for the content, accuracy, or security of external sites. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The examples and/or securities quoted (if any) are for illustration only and are not recommendatory. Any reliance you place on such information is strictly at your own risk. In no event will ATPL be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

By accessing this platform and its blog section, you acknowledge and agree to the Terms and Conditions of this website, Privacy Policy and Disclaimer.